#USA #San Francisco #AusperBio #AHB-137 #Med-Oligo

AusperBio Secures $63 Million in Series B2 Financing

In a significant advancement in the battle against chronic hepatitis B (CHB), AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. have announced the successful closing of $63 million in a Series B2 financing round. This funding is pivotal for the biotechnology company, focusing on innovative targeted oligonucleotide therapies aimed at achieving a functional cure for CHB.

The financing round garnered robust support from current investors, reflecting a strong belief in AusperBio's groundbreaking strategies that promise to evolve treatments for CHB. Notable backers included Qiming Venture Partners, alongside esteemed strategic investors, while existing syndicates like HanKang Capital and CDH Investments continued their partnership in this venture.

The funds raised will be instrumental in propelling the clinical development of AHB-137, AusperBio's flagship product candidate. This includes progressing through pivotal trials, launching various Phase II combination studies, and the expansion to global Phase II development. Furthermore, the financing will bolster the advancement of AusperBio’s proprietary Med-Oligo™ ASO platform and support the scaling-up of commercial manufacturing partnerships.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed gratitude towards the investors, emphasizing how their confidence correlates with the progress seen in clinical programs and the capabilities of the Med-Oligo™ platform. He stated, “This financing positions us to accelerate the pivotal development of AHB-137, expand our global clinical footprint, strengthen our platform and pipeline, and advance our long-term vision of delivering a functional cure for people living with chronic hepatitis B and beyond.”

Dr. Chris Yang, the co-founder and Chief Scientific Officer (CSO), described AHB-137 as the inaugural candidate from the Med-Oligo™ platform moving into pivotal development. Yang highlighted the therapy's promising potential as a backbone treatment for CHB, stating, “This financing will accelerate the development of our next generation combination therapy for CHB and support continued advancement of a pipeline of innovative targeted oligonucleotide therapeutics addressing a broad range of diseases with serious unmet medical need.”

William Hu, Managing Partner of Qiming Venture Partners, commended AusperBio’s pioneering approach, marking it as a differentiated strategy to tackle the CHB epidemic effectively. He remarked, “The company is well positioned to address one of the most serious unmet needs in global health,” showcasing immense confidence in AusperBio’s mission to deliver transformative therapies.

About AHB-137

AHB-137 stands as a novel unconjugated antisense oligonucleotide designed using AusperBio's proprietary Med-Oligo™ ASO technology platform and is currently an investigational medicine developed to achieve a functional cure for chronic hepatitis B. The clinical development phase has yielded promising data, which were readily showcased at leading global conferences including EASL and AASLD.

With its clinical trials in various stages, AHB-137 has already completed its global Phase I trial and is undergoing several Phase II trials, alongside a Phase III trial in China. These advancements, supported by a clear global strategy, signify a rapid progression towards potentially curing hepatitis B.

About AusperBio

AusperBio is a clinical-stage biopharmaceutical company operating in the USA and China, driven by the goal of enhancing oligonucleotide and targeted delivery technologies for revolutionary treatments. Focusing initially on achieving a functional cure for chronic hepatitis B, AusperBio developed a proprietary Med-Oligo™ ASO platform known for significantly improving the current standards in ASO therapeutics. This innovative platform facilitates treatments for a wide array of diseases, encompassing viral infections, metabolic conditions, genetic disorders, and immune diseases. AusperBio remains at the frontier of biopharmaceuticals, aiming to redefine patient care through innovative therapies.